Skip to content

Community-associated methicillin resistant Staphylococcus aureus infection

Community-associated methicillin resistant Staphylococcus aureus infection

CA-MRSA Infection

Year Number1 Mid-year population2 Cases / 100,000 population Number (%) resistant to mupirocin
2007 173 6,916,300 2.5 Data not available
2008 282 6,957,800 4.1 Data not available
2009 368 6,972,800 5.3 Data not available
2010 495 7,024,200 7.0 Data not available
2011 624 7,071,600 8.8 Data not available
2012 815 7,150,100 11.4 Data not available
2013 990 7,178,900 13.8 Data not available
2014 997 7,229,500 13.8 6 (0.60)
2015 1,046 7,291,300 14.3 6 (0.57)
2016 1,167 7,336,600 15.9 4 (0.34)
2017 1,258 7,393,200 17.0 5 (0.40)
2018 1,218 7,452,600 16.3 7 (0.57)
2019 1,236 7,507,900 16.5 4 (0.32)
2020 813 7,481,000 10.9 7 (0.86)
2021 582 7,413,100 7.9 1 (0.17)
2022 416 7,346,100 5.7 3 (0.72)
2023 469 7,536,100 6.2 4 (0.85)
2024 576 7,524,100 7.7 4 (0.69)
2025 427 7,498,900 5.7 4 (0.94)

Antimicrobial susceptibility pattern

Antimicrobial Year
2019 2020 2021 2022 2023 2024 2025
Clindamycin Cases tested 774 536 422 301 351 436 316
% Susceptible 66.9 68.3 67.8 71.4 68.4 62.4 64.9
% Resistant 33.1 31.5 32.0 28.6 31.3 37.4 34.8
Erythromycin Cases tested 852 571 533 381 429 537 402
% Susceptible 47.8 52.7 52.9 57.0 51.0 48.0 49.0
% Resistant 48.2 45.2 43.5 40.9 47.1 49.2 49.0
Doxycycline Cases tested 212 129 90 91 64 120 113
% Susceptible 87.3 85.3 91.1 89.0 85.9 87.5 76.1
% Resistant 3.3 3.1 1.1 7.7 4.7 4.2 8.0
Minocycline Cases tested 129 88 74 88 63 96 74
% Susceptible 100.0 100.0 100.0 90.9 96.8 92.7 95.9
% Resistant 0.0 0.0 0.0 8.0 3.2 7.3 4.1
Gentamicin Cases tested 788 500 453 326 371 458 340
% Susceptible 90.2 88.2 90.9 89.6 86.5 90.8 93.8
% Resistant 8.1 10.0 6.8 8.6 12.1 7.6 5.0
Co-trimoxazole Cases tested 981 622 458 328 384 461 348
% Susceptible 97.3 97.6 97.4 97.3 98.7 97.4 98.6
% Resistant 2.4 1.8 2.2 2.4 1.3 2.4 1.4
Total cases notified in year 1,236 813 582 416 469 576 427
Data updated as of 27 February 2026.